Treating diabetic retinopathy (DR) is still a significant challenge for clinicians and remains a leading cause of blindness worldwide. NovaGo Therapeutics is developing a human antibody therapy ...

This concept originated from an obvious feature of the unifying mechanism (Fig ... lesion of both human nonproliferative retinopathy and experimental diabetic retinopathy: acellular capillaries.

Table 1. Effect of anti-inflammatory therapy on diabetic retinopathy. Drugs Target Anti-inflammatory mechanisms Effect on DR pathology Ref. Steroids Glucocorticoid receptor Repress ...

With the advent of the 21st century, healthcare practitioners have witnessed a dramatic increase in the number of people being diagnosed with diabetes globally. According to the International ...

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

Diabetic retinopathy involves the changes for the blood vessels in your eye due to the high sugars that are in your body from diabetes, if you're a diabetic and you notice changes to your vision ...

US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic ...

Valo Health’s Rho kinase (ROCK) 1 and 2 inhibitor has failed to reduce the severity of diabetic retinopathy in a phase 2 trial, leading the Flagship-founded biotech to drop the candidate.

“We are enthusiastic about getting patients started in the OCU200 Phase 1 clinical trial and sharing not only safety but preliminary efficacy data as the study progresses,” said Dr. Huma Qamar, Chief ...